Weakening Advanced Prostate Cancer
Barakat: Making cancer more susceptible to chemotherapy
Advanced prostate cancer is difficult to treat because it's resistant to chemotherapy, radiation therapy, and hormonal therapy. "We need a better understanding of the underlying mechanisms in advanced disease," says postdoctoral fellow David Barakat, Ph.D. Working with two oncologists, Alan Friedman, M.D., and Ido Paz-Priel, M.D., he is studying a family of proteins called C/ EBPs, which control cell growth. "We previously found that C/EBPs, in cooperation with another protein, block cell death by increasing the expression of certain prosurvival genes," says Barakat.